Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.47 |
| ▸ | RARA | P10276 | 4/20 | 0.47 |
| ▸ | RARB | P10826 | 4/20 | 0.47 |
| ▸ | RARG | P13631 | 4/20 | 0.47 |
| ▸ | RXRG | P48443 | 10/20 | 0.42 |
| ▸ | RXRB | P28702 | 10/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081366 | 0.89 | RXRA (0.40) | RXRARARARARBRARGRXRG | |
| SCHEMBL7220993 | 0.82 | RXRA (0.45) | RXRARARARARBRARGRXRG | |
| SCHEMBL7080909 | 0.77 | RXRA (0.62) | RXRARARARARBRARGRXRG | |
| SCHEMBL727923 | 0.74 | RARB (0.70) | RXRARARARARBRARGRXRG | |
| SCHEMBL22250431 | 0.74 | RXRA (0.48) | RXRARARARARBRARGRXRG | |
| SCHEMBL29498857 | 0.74 | RXRA (0.48) | RXRARARARARBRARGRXRG | |
| SCHEMBL29498851 | 0.73 | RXRA (0.52) | RXRARXRGRXRB | |
| SCHEMBL22250446 | 0.73 | RXRA (0.52) | RXRARXRGRXRB | |
| SCHEMBL7088008 | 0.72 | RXRA (0.61) | RXRARARARARBRARGRXRG | |
| SCHEMBL22250447 | 0.72 | RXRA (0.49) | RXRARXRGRXRBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642273-B2 | Dermatology, vision defects, cardiovascular disorders, antiinflammatory | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-04 | — | — | US | claimed |
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-09 | — | — | US | claimed |
| US-6642273-B2 | Dermatology, vision defects, cardiovascular disorders, antiinflammatory | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-04 | — | — | US | disclosed |
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6534545-B1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | REL, DERL1, TLR7 | RXRA 30/4885RARA 39/4885RARB 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.